Iron i.v. in heart failure: ready for implementation?
作者信息
Brunner-La Rocca Hans-Peter, Crijns Harry J G M
机构信息
Department of Cardiology, Heart Failure Clinic, Maastricht University Medical Centre, Maastricht, The Netherlands
Department of Cardiology, Heart Failure Clinic, Maastricht University Medical Centre, Maastricht, The Netherlands.
出版信息
Eur Heart J. 2015 Mar 14;36(11):645-7. doi: 10.1093/eurheartj/ehu392. Epub 2014 Oct 21.
Abstract
摘要
相似文献
1
Iron i.v. in heart failure: ready for implementation?
Eur Heart J. 2015 Mar 14;36(11):645-7. doi: 10.1093/eurheartj/ehu392. Epub 2014 Oct 21.
2
Heart failure: Long-term iron therapy is beneficial in patients with HF.
Nat Rev Cardiol. 2014 Nov;11(11):622. doi: 10.1038/nrcardio.2014.147. Epub 2014 Sep 16.
3
Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency†.
Eur Heart J. 2015 Mar 14;36(11):657-68. doi: 10.1093/eurheartj/ehu385. Epub 2014 Aug 31.
4
[Iron deficiency : a new target in treating chronic heart failure ?].
Rev Med Suisse. 2016 Oct 19;12(535):1747-1751.
5
Monitoring iron therapy in chronic heart failure.
Eur J Heart Fail. 2013 Jul;15(7):711-2. doi: 10.1093/eurjhf/hft096.
6
Anemia and iron deficiency--new therapeutic targets in heart failure?
N Engl J Med. 2009 Dec 17;361(25):2475-7. doi: 10.1056/NEJMe0910313. Epub 2009 Nov 17.
7
Efficacy, safety and prognostic benefit of intravenous iron therapy with ferric carboxymaltose in patients with heart failure and left ventricular dysfunction.
Int J Cardiol. 2016 Jan 1;202:118-20. doi: 10.1016/j.ijcard.2015.08.204. Epub 2015 Sep 1.
8
The effect of intravenous ferric carboxymaltose on health-related quality of life in patients with chronic heart failure and iron deficiency: a subanalysis of the FAIR-HF study.
Eur Heart J. 2013 Jan;34(1):30-8. doi: 10.1093/eurheartj/ehr504. Epub 2012 Jan 31.
9
High-Dose Ferric Carboxymaltose in Patients With HFrEF Induces Significant Hypophosphatemia.
J Am Coll Cardiol. 2018 May 15;71(19):2270-2271. doi: 10.1016/j.jacc.2018.03.448.
10
Rationale and design of the AFFIRM-AHF trial: a randomised, double-blind, placebo-controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron-deficient patients admitted for acute heart failure.
Eur J Heart Fail. 2019 Dec;21(12):1651-1658. doi: 10.1002/ejhf.1710. Epub 2019 Dec 28.
引用本文的文献
1
Benefits of intravenous iron supplementation in heart failure.
Glob Cardiol Sci Pract. 2024 Mar 3;2024(2):e202410. doi: 10.21542/gcsp.2024.10.
2
Iron deficiency impairs contractility of human cardiomyocytes through decreased mitochondrial function.
Eur J Heart Fail. 2018 May;20(5):910-919. doi: 10.1002/ejhf.1154. Epub 2018 Feb 27.
3
Budget impact of intravenous iron therapy with ferric carboxymaltose in patients with chronic heart failure and iron deficiency in Germany.
ESC Heart Fail. 2017 Aug;4(3):274-281. doi: 10.1002/ehf2.12179. Epub 2017 Jul 3.
4
Is Correction of Iron Deficiency a New Addition to the Treatment of the Heart Failure?
Int J Mol Sci. 2015 Jun 18;16(6):14056-74. doi: 10.3390/ijms160614056.
本文引用的文献
1
Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency†.
Eur Heart J. 2015 Mar 14;36(11):657-68. doi: 10.1093/eurheartj/ehu385. Epub 2014 Aug 31.
2
Iron deficiency defined as depleted iron stores accompanied by unmet cellular iron requirements identifies patients at the highest risk of death after an episode of acute heart failure.
Eur Heart J. 2014 Sep 21;35(36):2468-76. doi: 10.1093/eurheartj/ehu235. Epub 2014 Jun 13.
3
IRON-HF study: a randomized trial to assess the effects of iron in heart failure patients with anemia.
Int J Cardiol. 2013 Oct 9;168(4):3439-42. doi: 10.1016/j.ijcard.2013.04.181. Epub 2013 May 13.
4
Iron status in patients with chronic heart failure.
Eur Heart J. 2013 Mar;34(11):827-34. doi: 10.1093/eurheartj/ehs377. Epub 2012 Nov 23.
5
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC.
Eur Heart J. 2012 Jul;33(14):1787-847. doi: 10.1093/eurheartj/ehs104. Epub 2012 May 19.
6
The effect of intravenous ferric carboxymaltose on health-related quality of life in patients with chronic heart failure and iron deficiency: a subanalysis of the FAIR-HF study.
Eur Heart J. 2013 Jan;34(1):30-8. doi: 10.1093/eurheartj/ehr504. Epub 2012 Jan 31.
7
Parenteral versus oral iron therapy for adults and children with chronic kidney disease.
Cochrane Database Syst Rev. 2012 Jan 18;1:CD007857. doi: 10.1002/14651858.CD007857.pub2.
8
Myocardial and systemic iron depletion in heart failure implications for anemia accompanying heart failure.
J Am Coll Cardiol. 2011 Jul 26;58(5):474-80. doi: 10.1016/j.jacc.2011.01.059.
9
Anemia and iron deficiency in heart failure: mechanisms and therapeutic approaches.
Nat Rev Cardiol. 2011 May 31;8(9):485-93. doi: 10.1038/nrcardio.2011.77.
10
Ferric carboxymaltose in patients with heart failure and iron deficiency.
N Engl J Med. 2009 Dec 17;361(25):2436-48. doi: 10.1056/NEJMoa0908355. Epub 2009 Nov 17.
Zotero 插件